

## **Global Autogenous Vaccines Market Report and Forecast 2023-2031**

Market Report | 2023-05-02 | 147 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

### **Report description:**

Global Autogenous Vaccines Market Report and Forecast 2023-2031

Global Autogenous Vaccines Market Outlook:

The global autogenous vaccines market value was USD 129.4 million in 2022, driven by the increasing need for more targeted and efficient disease control strategies in livestock, poultry, and aquaculture production across the globe. The market size is anticipated to grow at a CAGR of 5.6% during the forecast period of 2023-2031 to achieve a value of USD 212 million by 2031.

#### Introduction

Autogenous vaccines, also known as autovaccines or autogenous bacterins, are a type of customized vaccine developed specifically for individual animals or groups of animals within a specific farm or herd. Unlike commercial vaccines that are produced on a large scale for general use, autogenous vaccines are tailored to target specific pathogens present on a particular farm or in a specific population of animals. These vaccines are typically developed using the pathogens isolated from the affected animals and are designed to stimulate the animal's immune system to produce a specific immune response against those pathogens.

Autogenous vaccines play a crucial role in the management and control of infectious diseases in livestock, poultry, and aquaculture. They are particularly useful in situations where commercial vaccines may not provide adequate protection due to the unique strain or variant of the pathogen present in the specific farm or herd. Autogenous vaccines help to reduce the incidence and severity of infectious diseases, improve animal health and welfare, and minimize economic losses associated with disease outbreaks.

#### Key Trends in the Autogenous Vaccines Market

Some key trends involved in the autogenous vaccines market are as follows:

- **Increasing Demand for Customized Vaccines:** The demand for autogenous vaccines is growing as livestock producers, poultry farmers, and aquaculture operators recognize the need for customized solutions to address specific disease challenges on their farms. This trend is driven by the desire for more targeted and effective disease control measures and the increasing awareness of the limitations of commercial vaccines.
- **Advances in Biotechnology:** Technological advancements in biotechnology, including genomics and proteomics, have facilitated

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

the development of autogenous vaccines. These tools enable researchers to identify and characterize specific strains or variants of pathogens, allowing for the design and production of autogenous vaccines that are more tailored and effective

- Regulatory Support and Guidelines: Regulatory bodies and organizations governing animal health and production are increasingly recognizing the importance of autogenous vaccines and have established guidelines and regulations for their development and use. This trend provides a more streamlined and standardized approach to the production and application of autogenous vaccines, ensuring their safety, efficacy, and quality.
- Collaboration and Partnerships: Collaborations between research institutions, vaccine manufacturers, and livestock producers are becoming more common in the development and deployment of autogenous vaccines. These partnerships facilitate the sharing of knowledge, resources, and expertise, leading to the development of more effective and accessible autogenous vaccines.

## Autogenous Vaccines Market Segmentations

### Market Breakup by Strain Type

- Bacterial Strain
- Virus Strain

### Market Breakup by End User

- Veterinary Clinics
- Veterinary Hospitals
- Veterinary Research Institutes
- Others

### Market Breakup by Region

- North America
- United States of America
- Canada

- Europe
- United Kingdom
- Germany
- France
- Italy
- Others

- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others

- Latin America
- Brazil
- Argentina

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Mexico
- Others

- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

#### Autogenous Vaccines Market Scenario

The autogenous vaccine market is a rapidly evolving segment within the animal health industry. Autogenous vaccines are customized solutions developed for specific farms or herds to address the unique pathogen challenges they face. These vaccines are gaining traction as a valuable tool in disease management and prevention, offering tailored protection against pathogens that may not be effectively targeted by commercial vaccines.

The market for autogenous vaccines is primarily driven by the increasing need for more targeted and efficient disease control strategies in livestock, poultry, and aquaculture production. Factors such as the rising global demand for animal protein, the increasing incidence of infectious diseases, and the growing emphasis on animal welfare and health are fueling the demand for autogenous vaccines.

The market is witnessing technological advancements in areas such as genomics, proteomics, and bioinformatics, which enable researchers to identify and characterize specific strains or variants of pathogens. This knowledge helps in the development of highly specific autogenous vaccines with enhanced efficacy and safety profiles.

Regulatory bodies and organizations are recognizing the importance of autogenous vaccines and are providing guidelines and regulations to ensure their quality, safety, and efficacy. This regulatory support fosters standardization and increases confidence among producers and veterinarians in the use of autogenous vaccines.

Overall, the autogenous vaccine market presents significant growth opportunities. The increasing demand for customized disease control solutions, technological advancements, regulatory support, collaborations, and the emphasis on preventive healthcare are key drivers shaping the market landscape. As the awareness and adoption of autogenous vaccines continue to grow, the market is expected to expand, offering new avenues for innovation and improved animal health outcomes.

#### Autogenous Vaccines Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Newport Laboratories, Inc.
- Elanco Animal Health Inc
- Cambridge Technologies
- Hygieia Biological Laboratories
- AniCon Labor GmbH
- Boehringer Ingelheim International GmbH
- Ceva Biovac
- Phibro Animal Health Corporation
- Ace Laboratory Services
- Huvepharma, Inc.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## **Table of Contents:**

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
  - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Autogenous Vaccine Market Overview
  - 3.1 Global Autogenous Vaccine Market Historical Value (2016-2022)
  - 3.2 Global Autogenous Vaccine Market Forecast Value (2023-2031)
- 4 Global Autogenous Vaccine Market Landscape
  - 4.1 Global Autogenous Vaccine Developers Landscape
    - 4.1.1 Analysis by Year of Establishment
    - 4.1.2 Analysis by Company Size
    - 4.1.3 Analysis by Region
  - 4.2 Global Autogenous Vaccine Product Landscape
    - 4.2.1 Analysis by Strain Type
    - 4.2.2 Analysis by End User
- 5 Global Autogenous Vaccine Market Dynamics
  - 5.1 Market Drivers and Constraints
  - 5.2 SWOT Analysis
  - 5.3 Porter's Five Forces Model
  - 5.4 Key Demand Indicators
  - 5.5 Key Price Indicators
  - 5.6 Industry Events, Initiatives, and Trends
  - 5.7 Value Chain Analysis
- 6 Global Autogenous Vaccine Market Segmentation
  - 6.1 Global Autogenous Vaccine Market by Strain Type
    - 6.1.1 Market Overview
    - 6.1.2 Bacterial Strain
    - 6.1.3 Virus Strain
  - 6.2 Global Autogenous Vaccine Market by End User
    - 6.2.1 Market Overview
    - 6.2.2 Veterinary Clinics
    - 6.2.3 Veterinary Hospitals
    - 6.2.4 Veterinary Research Institutes

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 6.2.5 Others
- 6.3 Global Autogenous Vaccine Market by Region
  - 6.3.1 Market Overview
  - 6.3.2 North America
  - 6.3.3 Europe
  - 6.3.4 Asia Pacific
  - 6.3.5 Latin America
  - 6.3.6 Middle East and Africa
- 7 North America Autogenous Vaccine Market
  - 7.1 Market Share by Country
  - 7.2 United States of America
  - 7.3 Canada
- 8 Europe Autogenous Vaccine Market
  - 8.1 Market Share by Country
  - 8.2 United Kingdom
  - 8.3 Germany
  - 8.4 France
  - 8.5 Italy
  - 8.6 Others
- 9 Asia Pacific Autogenous Vaccine Market
  - 9.1 Market Share by Country
  - 9.2 China
  - 9.3 Japan
  - 9.4 India
  - 9.5 ASEAN
  - 9.6 Australia
  - 9.7 Others
- 10 Latin America Autogenous Vaccine Market
  - 10.1 Market Share by Country
  - 10.2 Brazil
  - 10.3 Argentina
  - 10.4 Mexico
  - 10.5 Others
- 11 Middle East and Africa Autogenous Vaccine Market
  - 11.1 Market Share by Country
  - 11.2 Saudi Arabia
  - 11.3 United Arab Emirates
  - 11.4 Nigeria
  - 11.5 South Africa
  - 11.6 Others
- 12 Patent Analysis
  - 12.1 Analysis by Type of Patent
  - 12.2 Analysis by Publication year
  - 12.3 Analysis by Issuing Authority
  - 12.4 Analysis by Patent Age
  - 12.5 Analysis by CPC Analysis
  - 12.6 Analysis by Patent Valuation

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 12.7 Analysis by Key Players
- 13 Grants Analysis
  - 13.1 Analysis by year
  - 13.2 Analysis by Amount Awarded
  - 13.3 Analysis by Issuing Authority
  - 13.4 Analysis by Grant Application
  - 13.5 Analysis by Funding Institute
  - 13.6 Analysis by NIH Departments
  - 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
  - 14.1 Analysis by Funding Instances
  - 14.2 Analysis by Type of Funding
  - 14.3 Analysis by Funding Amount
  - 14.4 Analysis by Leading Players
  - 14.5 Analysis by Leading Investors
  - 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
  - 15.1 Analysis by Partnership Instances
  - 15.2 Analysis by Type of Partnership
  - 15.3 Analysis by Leading Players
  - 15.4 Analysis by Geography
- 16 Regulatory Framework
  - 16.1 Regulatory Overview
    - 16.1.1 US FDA
    - 16.1.2 EU EMA
    - 16.1.3 INDIA CDSCO
    - 16.1.4 JAPAN PMDA
    - 16.1.5 Others
- 17 Supplier Landscape
  - 17.1 Newport Laboratories, Inc.
    - 17.1.1 Financial Analysis
    - 17.1.2 Product Portfolio
    - 17.1.3 Demographic Reach and Achievements
    - 17.1.4 Mergers and Acquisitions
    - 17.1.5 Certifications
  - 17.2 Elanco Animal Health Inc
    - 17.2.1 Financial Analysis
    - 17.2.2 Product Portfolio
    - 17.2.3 Demographic Reach and Achievements
    - 17.2.4 Mergers and Acquisitions
    - 17.2.5 Certifications
  - 17.3 Cambridge Technologies
    - 17.3.1 Financial Analysis
    - 17.3.2 Product Portfolio
    - 17.3.3 Demographic Reach and Achievements
    - 17.3.4 Mergers and Acquisitions
    - 17.3.5 Certifications

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17.4 Hygieia Biological Laboratories
  - 17.4.1 Financial Analysis
  - 17.4.2 Financial Portfolio
  - 17.4.3 Demographic Reach and Achievements
  - 17.4.4 Mergers and Acquisitions
  - 17.4.5 Certifications
- 17.5 AniCon Labor GmbH
  - 17.5.1 Financial Analysis
  - 17.5.2 Product Portfolio
  - 17.5.3 Demographic Reach and Achievements
  - 17.5.4 Mergers and Acquisitions
  - 17.5.5 Certifications
- 17.6 Boehringer Ingelheim International GmbH
  - 17.6.1 Financial Analysis
  - 17.6.2 Product Portfolio
  - 17.6.3 Demographic Reach and Achievements
  - 17.6.4 Mergers and Acquisitions
  - 17.6.5 Certifications
- 17.7 Ceva Biovac
  - 17.7.1 Financial Analysis
  - 17.7.2 Product Portfolio
  - 17.7.3 Demographic Reach and Achievements
  - 17.7.4 Mergers and Acquisitions
  - 17.7.5 Certifications
- 17.8 Phibro Animal Health Corporation
  - 17.8.1 Financial Analysis
  - 17.8.2 Product Portfolio
  - 17.8.3 Demographic Reach and Achievements
  - 17.8.4 Mergers and Acquisitions
  - 17.8.5 Certifications
- 17.9 Ace Laboratory Services
  - 17.9.1 Financial Analysis
  - 17.9.2 Product Portfolio
  - 17.9.3 Demographic Reach and Achievements
  - 17.9.4 Mergers and Acquisitions
  - 17.9.5 Certifications
- 17.10 Huvepharma, Inc.
  - 17.10.1 Financial Analysis
  - 17.10.2 Product Portfolio
  - 17.10.3 Demographic Reach and Achievements
  - 17.10.4 Mergers and Acquisitions
  - 17.10.5 Certifications
- 18 Global Autogenous Vaccine Market - Distribution Model (Additional Insight)
  - 18.1 Overview
  - 18.2 Potential Distributors
  - 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

20 Company Competitiveness Analysis (Additional Insight)

20.1 Very Small Companies

20.2 Small Companies

20.3 Mid-Sized Companies

20.4 Large Companies

20.5 Very Large Companies

21 Payment Methods (Additional Insight)

21.1 Government Funded

21.2 Private Insurance

21.3 Out-of-Pocket

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Global Autogenous Vaccines Market Report and Forecast 2023-2031**

Market Report | 2023-05-02 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com